Literature DB >> 31330336

TERTp Mutation Detection in Plasma by Droplet-Digital Polymerase Chain Reaction in Spinal Myxopapillary Ependymoma with Lung Metastases.

Anne Deniel1, Florent Marguet2, Ludivine Beaussire3, Anne-Claire Tobenas-Dujardin4, Christophe Peillon5, Marco-Achille Gambirasio6, Ovidiu Veresezan7, Nicolas Magne8, Frederic Di Fiore9, Annie Laquerrière2, Nasrin Sarafan-Vasseur3, Maxime Fontanilles10.   

Abstract

BACKGROUND: Spinal myxopapillary ependymoma (SP-MPE) is a subgroup of ependymomas in which after initial gross tumor resection, recurrences occur in more than half of the patients. Anaplastic transformation may also occur and contributes to intraneural and extraneural metastatic dissemination. Extraneural metastases from SP-MPE are rare and worsen the prognosis. In this situation, the noninvasive detection of recurrent somatic mutations in the circulating tumor DNA (ctDNA) from plasma is challenging. Telomerase-reverse transcriptase gene promoter (TERTp) mutation has been identified in a subset of ependymomas with aggressive behavior. CASE DESCRIPTION: We report on a patient with TERTp mutated SP-MPE presenting with an extraneural anaplastic metastatic dissemination after iterative local recurrences. From the initial SP-MPE to pleural anaplastic lesion, TERTp C228T mutation was present with allele frequency varying from 33% to 39%. Interestingly, TERTp mutation was also detected by droplet digital polymerase chain reaction in the plasma with a frequency of 2.1% at the time of pleural metastases, highlighting that ctDNA is released in plasma of patients suffering from SP-MPE with extraneural metastatic dissemination.
CONCLUSIONS: Despite the rarity of this evolution, plasmatic liquid biopsy appears to be a useful diagnostic and follow-up tool in a subset of primary brain tumors.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Circulating tumor DNA; Droplet digital PCR; Liquid biopsy; Metastasis; Spinal myxopapillary ependymoma; TERT promoter mutation

Year:  2019        PMID: 31330336     DOI: 10.1016/j.wneu.2019.07.111

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.

Authors:  Ngo Tat Trung; Nghiem Xuan Hoan; Pham Quang Trung; Mai Thanh Binh; Hoang Van Tong; Nguyen Linh Toan; Mai Hong Bang; Le Huu Song
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

Review 2.  Human TERT promoter mutations as a prognostic biomarker in glioma.

Authors:  Branka Powter; Sarah A Jeffreys; Heena Sareen; Adam Cooper; Daniel Brungs; Joseph Po; Tara Roberts; Eng-Siew Koh; Kieran F Scott; Mila Sajinovic; Joey Y Vessey; Paul de Souza; Therese M Becker
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-06       Impact factor: 4.553

Review 3.  An Overview of Intracranial Ependymomas in Adults.

Authors:  Giuseppe Lombardi; Alessandro Della Puppa; Marco Pizzi; Giulia Cerretti; Camilla Bonaudo; Marina Paola Gardiman; Angelo Dipasquale; Fabiana Gregucci; Alice Esposito; Debora De Bartolo; Vittorina Zagonel; Matteo Simonelli; Alba Fiorentino; Francois Ducray
Journal:  Cancers (Basel)       Date:  2021-12-05       Impact factor: 6.639

4.  Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.

Authors:  Maxime Fontanilles; Florent Marguet; Ludivine Beaussire; Nicolas Magne; Louis-Ferdinand Pépin; Cristina Alexandru; Isabelle Tennevet; Chantal Hanzen; Olivier Langlois; Fabrice Jardin; Annie Laquerrière; Nasrin Sarafan-Vasseur; Fréderic Di Fiore; Florian Clatot
Journal:  Acta Neuropathol Commun       Date:  2020-11-04       Impact factor: 7.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.